John C. Byrd

17.2k citations

158 papers · 8.8k indexed · 3 hit papers · h-index 51

Impact in

Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 0.05%
- Lymphoma Diagnosis and Treatment

Papers in

Genetics 125
- Chronic Lymphocytic Leukemia Research 125
Pathology and Forensic Medicine 103
- Lymphoma Diagnosis and Treatment 103

Co-authors: Ian W. Flinn Michael R. Grever R. Kanti Michael J. Keating Thomas J. Kipps Neil E. Kay Thomas S. Lin David Lucas
Journals: Blood (67 papers)Journal of Clinical Oncology (14 papers)British Journal of Haematology (10 papers)Cancer (9 papers)Clinical Cancer Research (6 papers)
Partner nations: United States United Kingdom Australia

In The Last Decade

John C. Byrd

156 papers receiving 8.6k citations

Hit Papers

align trajectories log scale

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia 2014 · 465 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2014 Blood
2004 New England Journal of Medicine
2002 Blood

Peers

Countries citing papers authored by John C. Byrd

Since Specialization

Citations

This map shows the geographic impact of John C. Byrd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Byrd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Byrd more than expected).

Fields of papers citing papers by John C. Byrd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John C. Byrd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Byrd. The network helps show where John C. Byrd may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John C. Byrd, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John C. Byrd Line = papers co-authored together John C. Byrd links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Comprehensive comparison of enzymatic and bisulfite DNA methylation analysis in clinically relevant samples Clinical Epigenetics ·Barrett Nuttall, Daniel Karl, Kathleen A. Burke, Katharina Ost, Kerrin Mendler, Pablo Cingolani, Steven W. Criscione, Masaya Yoshikai, Елена Бибикова, Veerendra Munugalavadla, John C. Byrd, Richard R. Furman, Jennifer R. Brown, Andrew Mortlock, Brian Dougherty, J. Carl Barrett, Maurizio Scaltriti, James Hadfield	2025	0
2	Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies Blood ·Sara Elgamal, 辰二郎大川, Aldo Mirabal Esparza, ثناء علي القباني, Zhihuan Zhou, Megan Johnstone, Jianmin Pan, N. Shesh, Alexander Khvat, Рубен Карапетян, Györy An, Елена А. Буланова, 西嶋寛之, Nikolay Savchuk, Iain Dukes, Amy Burd, Erin Hertlein, John C. Byrd	2024	1
3	Modulation of immune checkpoint molecule expression in mantle cell lymphoma Leukemia & lymphoma ·Bonnie K. Harrington, Esther F. Wheeler, 砂川恵, Alberto Pecorini, Youssef Youssef, Lisa Smith, W.A.R Wan Eny Zarina, Brett Klamer, Xiaoli Zhang, Meixiao Long, Robert A. Baiocchi, Kami J. Maddocks, Amy J. Johnson, John C. Byrd, Lapo Alinari	2019	23
4	Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Clinical Cancer Research ·Steven Coutré, Richard R. Furman, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, Jeffrey A. Jones, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Елена Александровна Леонова, Cathy Zhou, Elizabeth Bilotti, Danelle F. James, John C. Byrd, Susan O’Brien	2017	47
5	Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia British Journal of Haematology ·Tadeusz Robak, Andrzej Hellmann, Janusz Kłoczko, Javier Loscertales, Ewa Lech‐Marańda, John M. Pagel, Anthony R. Mato, John C. Byrd, Farrukh T. Awan, Holger Hebart, Nurmira Zhamangulova, Brian T. Hill, Michael Hallek, Amy J. Eisenfeld, Scott Stromatt, Ulrich Jaeger	2016	30
6	Toxicities and Related Outcomes of Elderly Patients (pts) (≥65 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611) Blood ·Bunshiro Saya, Jared C. Foster, Drew K. Seisler, Jacqueline M. Lafky, Arti Hurria, Aminah Jatoi, Harvey Jay Cohen, Hyman B. Muss, Nancy L. Bartlett, Bruce D. Cheson, Sin‐Ho Jung, John C. Byrd, John P. Leonard, Chadi Nabhan	2016	0
7	Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002 British Journal of Haematology ·David A. Rizzieri, Jeffrey L. Johnson, John C. Byrd, Gerard Lozanski, Kristie A. Blum, Bayard L. Powell, Thomas C. Shea, Sreenivasa Nattam, Eva Hoke, Bruce D. Cheson, Richard A. Larson	2014	57
8	Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies Leukemia & lymphoma ·Emilia Mahoney, Kami J. Maddocks, Joseph M. Flynn, Jeffrey A. Jones, Sara L. Cole, Xiaoli Zhang, John C. Byrd, Amy J. Wagoner Johnson	2013	22
9	Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies Clinical Cancer Research ·Yicheng Mao, Georgia Triantafillou, Erin Hertlein, William H. Towns, Matthew Stefanovski, Xiaokui Mo, David Jarjoura, Mitch A. Phelps, Guido Marcucci, Ly James Lee, David M. Goldenberg, Robert J. Lee, John C. Byrd, Natarajan Muthusamy	2012	26
10	Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness Annals of Oncology ·M. S. Czuczman, John P. Leonard, Sin‐Ho Jung, Jeffrey L. Johnson, Eric D. Hsi, John C. Byrd, Bruce D. Cheson	2012	51
11	Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia British Journal of Haematology ·Tait D. Shanafelt, John C. Byrd, Betsy LaPlant, Clive S. Zent, Tim G. Call, Charla Secreto, Michael R. Grever, Thomas S. Lin, Neil E. Kay	2009	10
12	Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma Leukemia & lymphoma ·Kristie A. Blum, Mehdi Hamadani, Gary Phillips, Gerard Lozanski, Amy J. Johnson, David Lucas, Lisa L. Smith, Robert A. Baiocchi, Thomas S. Lin, Pierluigi Porcu, Steven M. Devine, John C. Byrd	2009	6
13	Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS Journal of Chromatography B ·Hao Cheng, Zhongfa Liu, William Blum, John C. Byrd, Rebecca B. Klisovic, Michael R. Grever, Guido Marcucci, Kenneth K. Chan	2006	42
14	Prolonged follow‐up after initial therapy with 2‐chlorodeoxyadenosine in patients with indolent non‐Hodgkin lymphoma Cancer ·Kristie A. Blum, Jeffrey L. Johnson, Donna Niedzwiecki, Lawrence D. Piro, Alan Saven, B. A. Peterson, John C. Byrd, Bruce D. Cheson, (unknown)	2006	12
15	Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity Leukemia Research ·Ian W. Flinn, John C. Byrd, Nancy L. Bartlett, Thomas J. Kipps, John G. Gribben, Deborah A. Thomas, Richard A. Larson, R. Kanti, Rosemary Petric, Leslie Yolanda, Janice Gabrilove, Michael R. Grever	2005	78
16	Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions Blood ·Gerard Lozanski, Nyla A. Heerema, Ian W. Flinn, Lisa Smith, R. Irwin, Jennifer Webb, Mollie E. Moran, Margaret S. Lucas, Thomas S. Lin, 慎二井坪, John H. Proffitt, David Lucas, Michael R. Grever, John C. Byrd	2004	306
17	Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia Seminars in Oncology ·Donna Weber, Steven P. Treon, Christos Emmanouilides, Andrew R. Branagan, John C. Byrd, Joan Bladé, Eva Kimby	2003	65
18	Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma Cancer ·Jeremy G. Perkins, Joseph M. Flynn, Robin Howard, John C. Byrd	2002	98
19	Fludarabine-Related Pulmonary Toxicity CHEST Journal ·Donald L. Helman, John C. Byrd, Rocio Manzano Quintero, Andrew F. Shorr	2002	36
20	Renal medullary carcinoma: Clinical and therapeutic aspects of a newly described tumor Cancer ·Robert A. Avery, 秀雄増田, Charles J. Davis, Digamber S. Borgaonkar, John C. Byrd, 二朗斎藤	1996	87

About John C. Byrd

John C. Byrd is a scholar working on Genetics, Pathology and Forensic Medicine, Immunology, Hematology and Oncology, having authored 158 papers that have together received 8.8k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (125 papers), Lymphoma Diagnosis and Treatment (103 papers), Immunodeficiency and Autoimmune Disorders (42 papers), Monoclonal and Polyclonal Antibodies Research (22 papers), Acute Lymphoblastic Leukemia research (20 papers), Viral-associated cancers and disorders (12 papers), Advanced Breast Cancer Therapies (11 papers) and CAR-T cell therapy research (9 papers). The work is most often cited by research in Genetics (5.8k citations), Pathology and Forensic Medicine (5.0k citations), Immunology (3.2k citations), Hematology (1.3k citations) and Oncology (2.0k citations). John C. Byrd has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Ian W. Flinn, Michael R. Grever, R. Kanti, Michael J. Keating, Thomas J. Kipps, Neil E. Kay, Thomas S. Lin, David Lucas, Michael Pearson and Robin Howard. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact